Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $54.03 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +48.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), AGIOS PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 22.7%.
- Historical annual values: Fiscal year 2025: $54.03 million | Fiscal year 2024: $36.50 million | Fiscal year 2023: $26.82 million | Fiscal year 2022: $14.24 million | Fiscal year 2021: $0.00 | Fiscal year 2020: $0.00 | Fiscal year 2019: $117.91 million | Fiscal year 2018: $94.39 million | Fiscal year 2017: $43.01 million | Fiscal year 2016: $69.89 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: